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Abstract: Autoantibodies against apolipoprotein A-I (anti-apoA-I IgGs) are prevalent in
atherosclerosis-related conditions. It remains elusive whether they improve the prognostic accuracy
of the Global Registry of Acute Coronary Events (GRACE) score 2.0 (GS) in acute coronary syndromes
(ACS). In this prospective multicenter registry, 1713 ACS patients were included and followed for
1 year. The primary endpoint (major adverse cardiovascular events (MACE)) was defined as the
composite of myocardial infarction, stroke (including transient ischemic attack), or cardiovascular
(CV) death with individual events independently adjudicated. Plasma levels of anti-apoA-I IgGs
upon study inclusion were assessed using ELISA. The association between anti-apoA-I IgGs and
incident MACE was assessed using Cox models with splines and C-statistics. One-year MACE
incidence was 8.4% (144/1713). Anti-apoA-I IgG levels were associated with MACE with a non-linear
relationship (p = 0.01), which remained unchanged after adjusting for the GS (p = 0.04). The hazard
increased progressively across the two first anti-apoA-I IgG quartiles before decreasing thereafter.
Anti-apoA-I IgGs marginally improved the prognostic accuracy of the GS (c-statistics increased from
0.68 to 0.70). In this multicenter study, anti-apoA-I IgGs were predictive of incident MACE in ACS
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independently of the GS but in a nonlinear manner. The practical implications of these findings
remain to be defined.
Keywords: acute coronary syndrome; biomarkers; anti-apolipoprotein A-I autoantibodies; GRACE
score; C-statistics
1. Introduction
Over the last decades, the insight into the pathogenesis of atherosclerosis evolved from a
lipid-centered disease to a predominantly T-helper (Th)-1 driven immune response against various
antigens and auto-antigens within atherosclerotic plaques [1–3]. Among the latter, both cellular and
humoral autoimmune responses against different membrane proteins, native or modified lipoproteins
have been shown to modulate the course of atherogenesis either in a pro- or anti-atherogenic
manner [4,5]. Reflecting this intrinsic biological complexity, several autoantibodies have been detected
in sera of individuals and associated either with an increased or decreased cardiovascular (CV)
risk [6–10].
Among autoantibodies targeting lipoproteins potentially associated with increased CV risk,
those directed against apolipoprotein A-I (apoA-I), the major protein of high-density lipoprotein
(HDL), appear as appealing candidates. Indeed, most observational studies performed so far
indicate that antibodies against anti-apoA-I (anti-apoA-I IgGs) were an independent CV risk factor
predictive of poor prognosis, both in the general population and in different CV risk settings,
associated with a systemic pro-inflammatory profile and atherosclerotic plaque vulnerability [11–22].
Furthermore, in vitro and in vivo studies indicate that these autoantibodies can promote the loss of
HDL anti-oxidative function [15], induce sterile inflammation, atherogenesis, myocardial necrosis, and
death in experimental mouse models through activation of a specific innate immune receptor complex
consisting of Toll-like receptor (TLR)2, 4, and CD14 [23–25].
Nevertheless, it is unknown whether anti-apoA-I IgGs provide incremental prognostic value
over the Global Registry of Acute Coronary Events (GRACE) risk score 2.0 [26] after acute coronary
syndromes (ACS), and whether such an association could follow a nonlinear relationship with
the hazards, as recently shown for HDL-cholesterol regarding incident overall mortality [27].
Finally, we explored the associations between anti-apoA-I IgGs and other clinical and biological
variables available for this cohort [28,29], such as lipid profile, high sensitivity C-reactive protein
(hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-cTnT),
trimethyl-amine-N-oxide (TMAO), red blood cells, white blood cells, and platelets counts.
2. Experimental Section
2.1. Study Population
These findings are derived from the prospective multicenter Swiss ACS Cohort [28,30,31], as part
of the Special Program University Medicine (SPUM), which enrolled patients referred for coronary
angiography with a primary diagnosis of ACS at one of the participating University Hospitals (Zurich,
Bern, Lausanne, Geneva; Clinical Trials Registration number: NCT01000701; www.spum-acs.ch)
between December 2009 and October 2012. Of 2168 included Biomarker Cohort 1 patients, 1713 ACS
patients had available anti-apoA-I IgG measurements in addition to the previously described clinical
and laboratory data and were included in this study.
Briefly, inclusion criteria were: (1) patients older than 18 years admitted within 5 days (preferably
within 72 h) after pain onset with the main diagnosis of S–T segment (ST)-elevation myocardial
infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina (UA);
(2) persistent ST-segment elevation or depression, T-inversion or dynamic Electrocardiogram (ECG)
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changes, or new left bundle branch block (LBBB); (3) evidence of positive troponin by local laboratory
reference values with a rise and/or fall in serial troponin levels; (4) known coronary artery disease,
specified as status after myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous
coronary intervention, or newly documented ≥50% stenosis of an epicardial coronary artery during
the initial catheterization. Exclusion criteria comprised of (1) severe physical disability; (2) inability
to comprehend study; (3) less than 1 year of life expectancy for non-cardiac reasons. Patients were
followed-up for 1 year. All subjects gave written informed consent according to the declaration of
Helsinki, and the study was approved by the respective institutional review boards.
2.2. Definitions of Study Outcomes
The primary outcome of this study consisted of major adverse CV events (MACE), defined as a
composite of myocardial infarction (MI), stroke (including transient ischemic attack), or CV death, as
described previously [28,30,31]. Participants were first followed up at 1-year post-ACS by telephone
by a trained study nurse to attend a clinical visit. If patients were unable to attend the clinic visit,
follow-up was performed in the following order: (1) phone call, (2) postal mail or email, (3) through
family members, or (4) via primary care physician or cardiologist. Reviews of medical records and
clinical visits were conducted for the 1-year outcomes. Clinical endpoints were adjudicated by a
panel of three independent certified senior cardiologists blinded to anti-apoA-1 IgG results using
standardized pre-specified adjudication forms.
2.3. Biochemical Analyses
Blood was drawn from the arterial sheath at coronary angiography and centrifuged at 2700 × g
for 10 min at room temperature to obtain serum, and then frozen and stored in aliquots at −80 ◦C.
Routine laboratory tests (including lipid profile, hs-CRP, NT-proBNP, hs-cTnT, TMAO, red blood cells,
white blood cells, and platelets count) were performed according to laboratories of each Institution,
and the corresponding detailed analytical aspects have been reported earlier [28,29]. Estimated
glomerular filtration rate (eGFR; in mL/min per 1.73 m2) was calculated for each cohort using the
modification of Diet in Renal Disease study (MDRD) equation.
Anti-Apolipoprotein A-I IgG Levels
Anti-apoA-I IgGs were measured as previously described [11–13,16,20–22], using frozen EDTA
plasma aliquots, stored at −80 ◦C until analyses. Maxisorp plates (NuncTM, Roskilde, Denmark)
were coated with purified, human-derived delipidated apolipoprotein A-I (20 µg/mL; 50 µL/well)
for 1 h at 37 ◦C. After being washed, all wells were blocked for 1 h with 2% bovine serum albumin
(BSA) in a phosphate buffer solution (PBS) at 37 ◦C. Participants’ samples were also added to a
non-coated well to assess individual non-specific binding. After six washing cycles, a 50 µL/well of
signal antibody (alkaline phosphatase-conjugated anti-human IgG; Sigma-Aldrich, St Louis, MO, USA),
diluted 1:1000 in a PBS/BSA 2% solution, was added and incubated for 1 h at 37 ◦C. After washing
six more times, phosphatase substrate p-nitrophenyl-phosphate-disodium (Sigma-Aldrich, St Louis,
MO, USA) dissolved in a diethanolamine buffer (pH 9.8) was added and incubated for 20 min at 37 ◦C
(Molecular DevicesTM Filter Max F3, Molecular Devices, San Jose, CA, USA). Optical density (OD) was
determined at 405 nm, and each sample was tested in duplicate. Corresponding non-specific binding
was subtracted from mean OD for each sample. The specificity of detection against lipid-free and
unmodified apoA-I has been determined previously by conventional saturation tests, Western blot,
and LC-MS analyses [12]. At an intermediate value of 0.6 OD, the interassay coefficient of variation
was 9% (n = 5), and the intra-assay CV was 5% (n = 5).
2.4. Statistical Methods
The data were expressed as medians ± interquartile ranges for continuous variables and as
numbers and percentages for categorical variables. The correlation between anti-apoA-I IgG and other
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biomarkers was evaluated by nonparametric approach (Spearman rank correlation). Given the fact that
anti-apoA-I IgG seropositivity cut-off has not been defined nor validated on EDTA plasma, continuous
anti-apoA-I IgG levels in OD were categorized according to quartiles and/or used as a continuous
variable to assess the association with clinical outcomes. Time-to-first event or composite events were
analyzed censoring patients at 365 days or last valid contact date. Univariate and adjusted (for GRACE
score 2.0) associations of anti-apoA-I IgG categories with study endpoint was evaluated using Cox
proportional hazards models and expressed with hazard ratios (HRs) and 95% CI. The predictive
value of anti-apoA-I IgG over and above a reference model was assessed by Harrell’s C-statistics
calculated from a Cox proportional hazards regression model based on a logistic model using the
GRACE risk score as a reference [26]. To identify a possible nonlinear relationship between MACE risk
and anti-ApoA-I IgG continuous values, we used a Cox regression model with splines (with a degree of
freedom 2) [32]. A two-sided p-value <0.05 was considered statistically significant. Statistical analyses
were performed using STATA software® (Version 15, STATA Corp., College Station, TX, USA).
3. Results
3.1. Baseline Demographic and Biological Characteristics
Baseline characteristics of patients and pertinent data are summarized in Table 1. During the
1-year follow-up, 144 patients (8.4%) met the composite endpoint of MACE. Among them, 57 had a
myocardial infarction, 26 had a stroke, and 68 died from CV causes.
3.2. Associations with Major Adverse Cardiovascular Events (MACE) at 1-Year of Follow-Up
Traditional CV risk factors, as well as the GRACE risk score 2.0, hs-CRP, hs-cTnT, NT-proBNP,
TMAO levels, and anti-apoA-I IgG, upon study inclusion, were found to be higher in individuals with
MACE at 1-year post-ACS than in those without (Table 1). As shown in Tables 2 and 3, most of the
traditional CV risk factors, history of MI, renal function, and conventional biomarkers were significantly
associated with MACE at 1 year in univariate analyses. Of note, HDL cholesterol was not associated
with the study endpoint. As previously reported in the SPUM-ACS cohort [33], lower low-density
lipoprotein (LDL) and total cholesterol levels were significantly associated with a decreased risk
of MACE.
Anti-apoA-I IgG levels were associated with MACE (Table 3). Cumulative incidence curves
are represented in Figure 1 by anti-apoA-I IgGs quartiles. The adjustment for the GRACE score
did not modify the association (Table 4). The relationship between the incidence of MACE and
anti-apoA-I IgG levels was not linear since the cumulative incidence and the hazard ratio did not
change progressively with the anti-apoA-I IgG level (Figure 1, Table 3). The non-adjusted relationship
between the one-year risk of MACE and anti-apoA-I IgGs is depicted in more detail in Figure 2a.
An inverted U-shaped reminiscent association was apparent for MACE, with a progressively increasing
risk up to an anti-apoA-I IgG level of 1.0 OD, before an apparent decrease, difficult to interpret due
to the broadness of the 95% confidence interval. In an additional Cox model accounting for this
nonlinearity and adjusted for the GRACE score, the relation between the hazard and MACE remained
identical (Figure 2b). With this model, the non-linearity of the relationship (p = 0.0110) and the
association between MACE and anti-apoA-I IgG level (p = 0.0068) were statistically significant. Of note,
anti-apoA-I IgG values spanning from 0 to 1.0 OD represented 77% of all anti-apoA-1 IgGs values,
whereas values above 1.0 represented 23% of all anti-apoA-I IgG values on this cohort. Secondary
analyses revealed that the main driver of anti-apoA-I IgG-related MACE risk in the composite first
endpoint was the recurrence of MI as anti-apoA-I IgG levels were not predictive of stroke or CV deaths
(Figure S1, Supplementary Material).
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Table 1. Baseline characteristics.
Patient Characteristics All Patients (n = 1713) MACE * (n = 144) No MACE * (n = 1569)
Age, years
Median (IQR) 64 (54–74) 76 (64–81) 63 (53–73)
BMI, kg/m2
Median (IQR) 26.5 (24.2–29.4) 26.0 (24.1–30.4) 26.5 (24.2–29.4)
Missing data 23 9 14
Female, n (%) 363/1713 (21.2%) 35/144 (24.3%) 328/1569 (20.9%)
Current smoker, n (%) 690/1680 (41.1%) 44/138 (31.9%) 646/1542 (41.9%)
Diabetes history, n (%) 310/1713 (18.1%) 47/144 (32.6%) 263/1569 (16.8%)
MI history, n (%) 246/1713 (14.4%) 31/144 (21.5%) 215/1569 (13.7%)
Hypertension history, n (%) 993/1713 (58.0%) 100/144 (69.4%) 893/1569 (56.9%)
Dyslipidemia history, n (%) 1031/1711 (60.3%) 82/143 (57.3%) 949/1568 (60.5%)
Valvular disease history, n (%) 33/1713 (1.9%) 10/144 (6.9%) 23/1569 (1.5%)
Statin use, n (%) 503/1702 (29.6%) 50/141 (35.5%) 453/1561 (29.0%)
Beta-blocker use, n (%) 410/1699 (24.1%) 54/141 (59.3%) 356/1558 (22.8%)
GRACE score 2.0
Median (IQR) 123 (106–142) 144 (120–165) 121 (104–140)
Hs-CRP, mg/l
Median (IQR) 3.0 (1.2–8.0) 5.8 (2.3–18.9) 2.7 (1.1–7.6)
Missing data 203 11 192
Hs-cTnT, pg/L
Median (IQR) 0.22 (0.07–0.75) 0.51 (0.13–1.92) 0.21 (0.06–0.70)
Missing data 194 10 184
TMAO, µmol/L
Median (IQR) 2.93 (1.99–4.97) 4.25 (2.12–7.35) 2.86 (1.98–4.85)
Missing data 360 38 322
Anti-ApoA-I IgGs, OD
Median (IQR) 0.66 (0.44–0.97) 0.76 (0.49–0.98) 0.65 (0.44–0.97)
HDL, mmol/L
Median (IQR) 1.13 (0.94–1.39) 1.15 (0.94–1.46) 1.12 (0.94–1.38)
missing data 65 8 57
LDL, mmol/L
Ledian (IQR) 3.08 (2.34–3.84) 2.72 (2.04–3.45) 3.11 (2.39–3.86)
Missing data 68 8 60
Total cholesterol, mmol/L
Median (IQR) 4.86 (4.10–5.70) 4.5 (3.7–5.2) 4.9 (4.1–5.8)
Missing data 49 7 42
Triglyceride, mmol/L
Median (IQR) 1.02 (0.69–1.60) 0.95 (0.65–1.33) 1.04 (0.70–1.60)
Missing data 58 7 51
Creatinine
Median (IQR) 76.0 (65.0–91.0) 89.0 (71.8–114.3) 75.0 (65.0–90.0)
eGFR
Median (IQR) 90.9 (73.5–108.8) 74.6 (55.8–92.3) 92.1 (75.4–109.6)
Missing data 5 0 5
Systolic blood pressure
Median (IQR) 129 (114–145) 129 (110–142) 129 (115–145)
Diastolic blood pressure
Median (IQR) 75.0 (65.0–84.0) 72.0 (61.0–80.3) 75.0 (65.0–84.0)
Missing data 17 0 17
Renal failure (eGFR < 60), n (%) 214/1708 (12.5%) 43/144 (29.8%) 171/1564 (9.0%)
* one-year follow-up; Abbreviations: BMI—body mass index; SBP—Systolic blood pressure; DBP—diastolic
blood pressure; MACE—major adverse cardiovascular events; IQR—interquartile range; MI—myocardial
infarction; GRACE—Global Registry of Acute Coronary Events; Hs-CRP—high sensitivity C-reactive protein;
Hs-cTnT—high-sensitivity troponin T; TMAO—trimethyl-amine-N-oxide; Anti-ApoA-I IgGs—autoantibodies
against apolipoprotein A-I; OD—optical density; HDL—high-density lipoprotein; LDL—low-density lipoprotein;
eGFR—estimated glomerular filtration rate.
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Table 2. One-year cumulative major adverse cardiovascular events (MACE) incidence according to
univariate analyses.
Predictors Levels N MACE/N Total One-Year Cumulative Incidence ofMACE (95% CI) p-Value *
Age 26–54 y 17/450 3.8 (2.0–5.6) <0.0001
55–64 y 22/443 5.0 (3.0–7.0)
65–74 y 32/418 7.7 (5.1–10.3)
≥75 y 73/402 18.4 (14.5–22.1)
BMI, kg/m2 20–24.9 49/554 9.0 (6.5–11.3) 0.1569
25–29.9 50/767 6.6 (4.8–8.4)
30–34.9 26/283 9.3 (5.8–12.6)
≥35 10/86 12.0 (4.7–18.8)
GRACE score ≤99 9/318 2.9 (1.0–4.7) <0.0001
100–119 25/453 5.6 (3.4–7.7)
120–139 29/456 6.4 (4.1–8.7)
140–159 37/303 12.3 (8.5–16.0)
≥160 44/183 24.3 (17.8–30.3)
Gender female 35/363 9.8 (6.6–12.8) 0.3095
male 109/1350 8.2 (6.7–9.6)
Diabetes history no 97/1403 7.0 (5.6–8.3) <0.0001
yes 47/310 15.5 (11.3–19.4)
MI history No 113/1467 7.8 (6.4–9.2) 0.0124
yes 31/246 12.9 (8.5–17.0)
Hypertension
history no 44/720 6.2 (4.4–7.9) 0.0041
yes 100/993 10.2 (8.3–12.1)
Dyslipidemia
history no 61/680 9.1 (6.9–7.9) 0.4057
yes 82/1031 8.0 (6.4–12.1)
Valvular history no 134/1680 8.1 (6.8–9.4) <0.0001
yes 10/33 30.3 (12.7–44.3)
Current smoker no 96/990 9.6 (7.7–11.4) 0.0251
yes 44/690 6.5 (4.6–8.3)
Hs-CRP, mg/L 0–0.99 12/299 4.1 (1.8–6.3) <0.0001
1–1.99 18/280 6.5 (3.5–9.3)
2–9.99 55/614 9.1 (6.8–11.4)
≥10 48/317 15.4 (11.3–19.4)
Hs-cTnT, ng/L 0–0.14 40/647 6.3 (4.4–8.1) 0.0001
0.15–0.52 29/379 7.8 (5.0–10.5)
>0.52 65/493 13.3 (10.3–16.3)
TMAO, µmol/L <2 25/340 7.4 (4.6–10.2) 0.0001
2–2.99 12/350 3.5 (1.5–5.4)
3–3.99 13/206 6.4 (3.0–9.7)
4–6.99 27/257 10.6 (6.7–14.3)
≥7 29/200 14.7 (9.6–19.4)
* Log-rank test. Abbreviations: BMI—body mass index; GRACE—Global Registry of Acute Coronary Events;
MI—myocardial infarction; Hs-CRP—high sensitivity C-reactive protein; Hs-cTnT—high-sensitivity troponin
T; TMAO—trimethyl-amine-N-oxide.
J. Clin. Med. 2019, 8, 1002 7 of 14
Table 3. One-year cumulative major adverse cardiovascular events (MACE) incidence according to
univariate analyses.
Predictors Levels N MACE/N Total One-Year Cumulative Incidence ofMACE (95% CI) p-Value *
Anti-ApoA-I IgGs,
OD ≤0.45 31/442 7.1 (4.7–9.5) 0.0323
0.46–0.65 24/396 6.1 (3.7–8.5)
0.66–0.95 48/425 11.5 (8.4–14.5)
>0.95 41/450 9.2 (6.5–11.9)
HDL, mmol/L <1 41/511 8.2 (5.7–10.5) 0.6210
1–1.3 48/626 7.8 (5.6–9.8)
>1.3 47/511 9.3 (6.7–11.8)
LDL, mmol/L <2.5 59/492 12.3 (9.3–15.1) 0.0005
2.5–3.5 46/580 8.0 (5.8–10.2)
>3.5 31/573 5.5 (3.6–7.3)
Total cholesterol,
mmol/L <4.5 98/606 11.4 (8.8–13.9) 0.0027
4.5–5.5 41/573 7.2 (5.1–9.3)
>5.5 28/485 5.9 (3.7–7.9)
Triglyceride,
mmol/L <0.80 46/527 8.8 (6.3–11.2) 0.0653
0.80–1.30 56/564 10.1 (7.6–12.6)
>1.30 35/564 6.3 (4.2–8.3)
Creatinine, µmol/L <70 31/606 5.2 (3.4–7.0) <0.0001
70–85 35/550 6.5 (4.4–8.5)
>85 78/557 14.2 (11.2–17.1)
NT-proBNP, ng/L <200 18/511 3.6 (1.9–5.2) <0.0001
200–1000 36/514 7.1 (4.8–9.3)
>1000 80/493 16.5 (13.1–19.7)
SBP, mmHg <120 47/561 8.4 (6.1–10.7) 0.5490
120–140 60/649 9.4 (7.1–11.6)
>140 37/503 7.5 (5.2–9.8)
DBP, mmHg <70 59/602 9.9 (7.5–12.3) 0.2120
70–80 49/565 8.8 (6.4–11.1)
>80 36/529 6.9 (4.7–9.0)
eGFR <60 mL/min no 101/1595 6.9 (5.6–8.1) <0.0001
yes 43/257 20.3 (14.7–25.6)
* Log-rank test. Abbreviations: MACE—major adverse cardiovascular events; Anti-ApoA-I IgGs—autoantibodies
against apolipoprotein A-I; OD—optical density; HDL—high-density lipoprotein; LDL—low-density lipoprotein;
NT-proBNP—N-terminal pro-brain natriuretic peptide; SBP—Systolic blood pressure; DBP—diastolic blood pressure;
eGFR—estimated glomerular filtration rate.
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Table 4. Autoantibodies against apolipoprotein A-I (Anti-apoA-I IgGs) and major adverse
cardiovascular events (MACE) (myocardial infarction, stroke, or cardiovascular (CV) death) risk
according to Cox-regression analyses.
Predictors Unadjusted HR (95% CI) p-Value Adjusted HR (95% CI) ** p-Value
Anti-ApoA-I IgGs OD
≤0.45, Q1 Reference group 0.0338 * Reference group 0.0496 *
0.46–0.65, Q2 0.85 (0.50–1.46) 0.5625 0.82 (0.48–1.40) 0.4682
0.66–0.95, Q3 1.64 (1.04–2.57) 0.0322 1.56 (0.99–2.44) 0.0558
>0.95, Q4 1.30 (0.82–2.08) 0.2657 1.23 (0.77–1.97) 0.3808
GRACE score 2.0
≤99 Reference group <0.0001 * Reference group <0.0001 *
100–119 1.96 (0.92–4.20) 0.0931 1.99 (0.93–4.26) 0.0772
120–139 2.27 (1.07–4.79) 0.0321 2.25 (1.07–4.76) 0.0332
140–159 4.44 (2.14–9.19) <0.0001 4.44 (2.14–9.20) <0.0001
≥160 9.44 (4.61–19.35) <0.0001 9.36 (4.57–19.18) <0.0001
* p-Value for the overall association between the factor (all levels) and risk of MACE; ** Adjusted for the GRACE score
2.0. Abbreviations: HR—hazard ratio; OD—optical density; GRACE—Global Registry of Acute Coronary Events.
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(OD)) in univariate analyses (black line). (b) Hazard ratio for MACE according to anti-apoA-I IgG
levels (black line) adjusted for the categories of the Global Registry of Acute Coronary Events (GRACE)
score 2.0. The vertical black lines above the x-axis represent the distribution of anti-apoA-I IgG levels in
the study population: each vertical line represents the value of one participant. In both panels, the grey
lines represent the 95% confidence interval. The distribution of anti-apoA-I IgG values was as followed:
from 0 to 0.5 OD: n = 544 (31.8%); >0.5 and ≤1.0: n = 774 (45.2%); >1.0 and ≤1.5: n = 292 (17.0%); >1.5
and ≤2.0: n = 89 (5.2%); >2.0: n = 14 (0.8%).
C-statistics confirmed that anti-apoA-I IgG levels were a modest but significant predictor for
MACE. When added to the GRACE risk score for MACE prediction at one year, anti-apoA-I IgG
marginally improved the prognostic accuracy of the model: C-statistics changed from 0.680 for Cox
model with the categories of a GRACE risk score to 0.698 for Cox model combining the categories of
GRACE risk score and anti-apoA-I IgG levels in a continuous way.
3.3. Anti-apoA-I IgG Associations in Acute Coronary Syndrome (ACS)
To further explore the associations between anti-apoA-I IgGs and patients’ clinical and biological
characteristics in ACS, we analyzed the distribution of the latter according to anti-apoA-I IgG quartiles.
As shown in Tables 5 and 6, an inverse association was observed with the prevalence of diabetes that
decreased among the increasing anti-apoA-I IgG categories, and a trend toward increased representation
of valvular disease along anti-apoA-I IgG categories was noted. Furthermore, Spearman correlation
coefficients showed modest but statistically significant positive associations between anti-apoA-I IgG
levels and NT-proBNP and hemoglobin levels, while negative associations were retrieved between
anti-apoA-I IgG and neutrophil, eosinophil, and platelet counts (Table S1, Supplementary Material).
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Close to significant associations (p ≤0.1) were noted with age, hs-cTnT, hemoglobin, hematocrit,
leucocytes, creatinine, total cholesterol, and triglyceride levels. No other significant association was
retrieved, notably with TMAO levels (Table S1). None of these anti-apoA-I IgG associations would
have remained significant after the application of Bonferroni correction (significance threshold: 0.05/24:
p = 0.002).
Table 5. Exploring the factors associated with autoantibodies against apolipoprotein A-I (anti-apoA-I
IgG) levels.
Anti-apoA-I IgG Levels
All Patients ≤0.45 Q1 >0.45 and ≤0.65 Q2 >0.65 and ≤0.95 Q3 >0.95 Q4 P *
Age, years
median (IQR) 64 (54–74) 63 (53–74) 63 (54–74) 64 (54–72) 65 (55–75) 0.1787
26–54 y 450 (26.3%) 122 (27.6%) 111 (28.0%) 109 (25.6%) 108 (24.0%)
55–64 y 443 (25.9%) 121 (27.4%) 102 (25.8%) 114 (26.8%) 106 (23.6%)
65–74 y 418 (24.4%) 99 (22.4%) 92 (23.2%) 110 (25.9%) 117 (26.0%)
≥75 y 402 (23.5%) 100 (22.6%) 91 (23.0%) 92 (21.6%) 119 (26.4%)
BMI, kg/m2
median (IQR) 26.5 (24.2–29.4) 26.2 (24.2–29.3) 26.4 (24.2–29.3) 26.8 (24.3–29.7) 26.6 (24.2–29.4) 0.6434
20–24.9 554 (32.8%) 154 (35.2%) 128 (32.4%) 134 (32.2%) 138 (31.3%)
25–29.9 767 (45.4%) 189 (43.2%) 187 (47.3%) 182 (43.8%) 209 (47.4%)
30–34.9 283 (16.7%) 75 (17.1%) 62 (15.7%) 73 (17.5%) 73 (16.6%)
≥35 86 (5.1%) 20 (4.6%) 18 (4.6%) 27 (6.5%) 21 (4.8%)
missing data 23 4 1 9 9
Female, n (%) 363/1713 (21.2%) 102/442 (23.1%) 87/396 (22.0%) 93/425 (21.9%) 81/450 (18.0%) 0.2669
Current smoker, n (%) 690/1680 (41.1%) 174/436 (39.9%) 147/390 (37.7%) 183/419 (43.7%) 186/435 (42.8%) 0.2875
Diabetes history, n (%) 310/1713 (18.1%) 97/442 (21.9%) 66/396 (16.7%) 83/425 (19.5%) 64/450 (14.2%) 0.0177
Hypertension history,
n (%) 720/1713 (42.0%) 248/442 (56.1%) 234/396 (59.1%) 247/425 (58.1%) 264/450 (58.7%) 0.8191
MI history, n (%) 246/1713 (14.4) 53/442 (12.0%) 52/396 (13.1%) 73/425 (17.2%) 68/450 (15.1%) 0.1416
Cholesterolemia
history, n (%)
1031/1711
(60.3%) 276/441 (62.6%) 247/395 (62.5%) 257/425 (60.5%) 251/450 (55.8%) 0.1311
Valvular history, n (%) 33/1713 (1.9%) 4/442 (0.9%) 6/396 (1.5%) 8/425 (1.9%) 15/450 (3.3%) 0.0572
GRACE score
median (IQR) 123 (106–142) 123 (106–142) 123 (106–140) 123 (104–144) 123 (106–143) 0.7916
≤99 318 (18.6%) 83 (18.8%) 74 (18.7%) 84 (19.8%) 77 (17.1%)
100–119 453 (26.4%) 121 (27.4%) 110 (27.8%) 100 (23.5%) 122 (27.1%)
120–139 456 (26.6%) 115 (26.0%) 103 (26.0%) 115 (27.1%) 123 (27.3%)
140–159 303 (17.7%) 84 (19.0%) 65 (16.4%) 76 (17.9%) 78 (17.3%)
≥160 183 (10.7%) 39 (8.8%) 44 (11.1%) 50 (11.8%) 50 (11.1%)
CRP, mg/L
median (IQR) 3.0 (1.2–8.0) 2.60 (1.10–7.70) 2.70 (1.00–6.40) 3.30 (1.40–8.25) 3.10 (1.30–9.20) 0.1704
0–0.99 299 (19.8%) 77 (20.2%) 80 (22.7%) 63 (16.6%) 79 (19.9%)
1–1.99 280 (18.5%) 76 (19.9%) 67 (19.0%) 71 (18.7%) 66 (16.6%)
2–9.99 614 (40.7%) 149 (39.1%) 141 (39.9%) 166 (43.8%) 158 (39.8%)
≥10 317 (21.0%) 79 (20.7%) 65 (18.4%) 79 (20.8%) 94 (23.7%)
missing data 203 61 43 46 53
Hs-cTnT, ng/L
median (IQR) 0.22 (0.07–0.75) 0.20 (0.06–0.67) 0.21 (0.06–0.66) 0.24 (0.07–0.87) 0.26 (0.07–0.83) 0.1947
0–0.14 647 (42.6%) 172 (45.0%) 155 (43.7%) 158 (41.1%) 162 (40.7%)
0.15–0.52 379 (25.0%) 98 (25.7%) 86 (24.2%) 93 (24.2%) 102 (25.6%)
>0.52 493 (32.5%) 112 (29.3%) 114 (32.1%) 133 (34.6%) 134 (33.7%)
missing data 194 60 41 41 52
TMAO
median (IQR) 2.93 (1.99–4.97) 2.85 (1.89–4.97) 2.96 (2.01–4.98) 2.93 (2.00–4.46) 3.05 (2.07–5.43) 0.4744
<2 340 (25.1%) 98 (28.3%) 74 (23.9%) 83 (25.1%) 85 (23.2%)
2–2.99 350 (25.9%) 87 (25.1%) 84 (27.2%) 86 (26.0%) 93 (25.3%)
3–3.99 206 (15.2%) 42 (12.1%) 51 (16.5%) 60 (18.1%) 53 (14.4%)
4–6.99 257 (19.0%) 66 (19.1%) 50 (16.2%) 63 (19.0%) 78 (21.3%)
≥7 200 (14.8%) 53 (15.3%) 50 (16.2%) 39 (11.8%) 58 (15.8%)
missing data 360 96 87 94 83
* Kruskal-Wallis or Chi-2 tests (Fisher exact test for liver history). Abbreviations: IQR—interquartile range;
BMI—body mass index; MI—myocardial infarction; GRACE—Global Registry of Acute Coronary Events;
CRP—C-reactive protein; hs-cTnT—high-sensitivity troponin T; TMAO—trimethyl-amine-N-oxide.
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Table 6. Exploring the factors associated with autoantibodies against apolipoprotein A-I (anti-apoA-I
IgG) levels.
Anti-apoA-I IgG Levels
All Patients ≤0.45 Q1 >0.45 and ≤0.65 Q2 >0.65 and ≤0.95 Q3 >0.95 Q4 P *
SBP, mmHg
Median (IQR) 129 (114–145) 129 (115–145) 129 (115–144) 128 (112–145) 130 (114–146) 0.9714
Missing data 0 0 0 0 0
DBP, mmHg
Median (IQR) 75 (65–84) 75 (66–84) 75 (65–84) 73 (65–84) 74 (63–84) 0.6476
Missing data 17 7 2 4 4
Hemoglobin, g/L
Median (IQR) 138 (127–149) 137 (124–149) 138 (126–148) 139 (129–148) 139 (128–150) 0.3715
Missing data 87 30 19 19 19
Hematocrit, %
Median (IQR) 41 (38–43.3) 41 (37–43) 40 (37–43) 41 (38–44) 41 (38–44) 0.2161
Missing data 76 26 14 18 18
Leucocytes, G/L
Median (IQR) 9.6 (7.4–12.1) 9.5 (7.3–12.0) 9.2 (7.1–12.0) 9.8 (7.9–12.1) 9.8 (7.6–12.3) 0.0340
Missing data 73 25 14 17 17
Erythrocytes, T/L
Median (IQR) 4.5 (4.1–4.8) 4.5 (4.1–4.9) 4.4 (4.1–4.8) 4.5 (4.2–4.8) 4.5 (4.1–4.8) 0.3240
Missing data 84 28 17 19 20
Lymphocytes, %
Median (IQR) 1.62 (1.16–2.35) 1.67 (1.20–2.55) 1.54 (1.09–2.31) 1.69 (1.19–2.34) 1.58 (1.11–2.22) 0.0526
Missing data 395 118 95 87 95
Neutrophils, G/L
Median (IQR) 7.3 (5.3 to 10.0) 7.0 (5.0 to 9.7) 7.2 (4.7 to 10.1) 7.4 (5.5 to 9.9) 7.6 (5.5 to 10.1) 0.1500
Missing data 412 122 97 93 100
Monocytes, %
Median (IQR) 0.62 (0.45 to 0.95) 0.63 (0.45 to 1.05) 0.56 (0.41 to 0.92) 0.64 (0.48 to 0.99) 0.61 (0.45 to 0.90) 0.1220
Missing data 398 118 96 88 96
Basophils, %
Median (IQR) 0.03 (0.01–0.07) 0.03 (0.02–0.08) 0.03 (0.01–0.07) 0.03 (0.01–0.07) 0.03 (0.01–0.06) 0.7491
Missing data 399 118 95 88 98
Eosinophils, %
Median (IQR) 0.08 (0.02–0.19) 0.10 (0.03–0.21) 0.08 80.03–0.20) 0.07 (0.02–0.17) 0.07 (0.02–0.16) 0.0237
Missing data 401 119 96 88 98
Thromboctyes, G/L
Median (IQR) 215 (183–257) 226 (188–272) 211 (179–250) 218 (185–253) 208 (176–255) 0.0026
Missing data 85 27 15 21 22
Total cholesterol, mmol/L
Median (IQR) 4.9 (4.1–5.7) 4.9 (4.1–5.8) 4.9 (4.0–5.8) 4.9 (4.1–5.7) 4.7 (4.0–5.6) 0.1602
Missing data 49 13 13 11 12
HDL, mmol/L
Median (IQR) 1.13 (0.69–1.60) 1.14 (0.93–1.40) 1.14 (0.96–1.40) 1.13 (0.94–1.40) 1.10 (0.93–1.33) 0.2852
Missing data 65 20 15 14 16
LDL, mmol/L
Median (IQR) 308 (2.34–3.84) 3.07 (2.32–3.94) 3.13 (2.40–3.82) 3.08 (2.37–3.81) 2.99 (2.26–3.81) 0.7418
Missing data 68 20 16 16 16
Triglyceride
Median (IQR) 1.02 (0.69–1.60) 1.08 (0.72–1.70) 1.05 (0.69–1.68) 1.00 (0.66–1.51) 0.99 (0.69–1.48) 0.2165
Missing data 58 17 15 13 13
Creatinine, µmol/L
Median (IQR) 76 (65–91) 75 (64–88) 76 (66–91) 76 (65–92) 77 (66–92) 0.3484
Missing data 0 0 0 0 0
NT-ProBNP, ng/L
Median (IQR) 414 (131–1436) 386 (118–1462) 355 (129–1196) 433 (132–1627) 544 (159–1633) 0.0390
Missing data 195 60 41 42 52
eGFR, mL/min
Median (IQR) 90.9 (73.5–108.8) 92.1 (75.8–110.9) 91.0 (73.5–107.2) 89.8 (73.5–108.3) 90.7 (70.5–108.6) 0.4791
Missing data 5 1 1 2 1
Renal failure (eGFR <60), n
(%) 214/1708 47/441 53/395 56/423 58/449 0.5828
* Kruskal-Wallis or Chi-2 tests (Fisher exact test for liver history). Abbreviations: Anti-apoA-I IgG—autoantibodies
against apolipoprotein A-I; SBP—systolic blood pressure; DBP—diastolic blood pressure; IQR—interquartile range;
HDL—high-density lipoprotein; LDL—low-density lipoprotein; NT-ProBNP—N-terminal pro-brain natriuretic
peptide; eGFR—estimated glomerular filtration rate.
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4. Discussion
The key finding of the present study is that anti-apoA-I IgG was predictive of incident MACE
independently of the GRACE score 2.0, one of the strongest prognostic stratification tools currently
validated in ACS. Furthermore, the prognostic accuracy of the GRACE score was slightly improved
(+2%) by adding anti-apoA-I IgGs to it, according to C-statistics. Because of the important controversy
regarding the reliability of C-statistics comparison and reclassification statistics (net reclassification
index and integrated discrimination index) in embedded models due to the important false positive
findings [34,35], we did not perform further statistical analyses to interpret this difference. Indeed, we
feel that a 2% increase in C-statistics is unlikely to be clinically meaningful or to change current clinical
practice in ACS. Nevertheless, these results strengthen the proof-of-principle that anti-apoA-I IgGs are
predictive of a poor CV prognosis, as suggested earlier in the general population and in different high
CV risk settings [11–17,20–22].
The second notable finding of this study is that the association between anti-apoA-I IgGs and
MACE was not linear over the full range of anti-apoA-I IgG values. Indeed, the relationship was linear
for the first 87% anti-apoA-I IgG values but started to decline for the remaining 23% highest anti-apoA-I
IgG values. According to Cox regression models with splines confirming the significant nature of
this non-linear relationship with MACE, we hypothesized that anti-apoA-I IgGs would mirror the
U-shaped relationship between HDL-cholesterol and outcomes reported lately [27]. Nevertheless,
there was no association between HDL-cholesterol and MACE or between HDL-cholesterol and
anti-apoA-I IgGs in this study. Furthermore, due to the small number of events in this last 23% portion
of anti-apoA-I IgG values, the confidence intervals of our regression model increased, preventing us
from concluding on a possibly inverted U-shape relationship with MACE or the occurrence of a plateau
at high anti-apoA-I IgG values. To the best of our knowledge, this is the first report of a non-linear
association between anti-apoA-I IgG levels and MACE. Whether this non-linear association is specific
for the ACS population is still elusive, but should be taken into account in future studies in order to
avoid possible false negative findings related to the classic assumption of a proportional risk increase
between anti-apoA-I IgG levels and hazards.
To further explore the possible associations between biological and clinical parameters with
anti-apoA-I IgG levels in ACS, our linear regression analyses of anti-apoA-I IgG quartiles did not
identify specific items markedly associated with anti-apoA-I IgG, and we did not reproduce the often
reported association with previous MI history [11,20–22]. Interestingly, a trend was observed with the
presence of valvular diseases, and an inverse relationship with the history of diabetes. This possible
association with the presence of valvular diseases is in line with the concept supporting a causal role
between humoral autoimmunity and different valvular diseases historically exemplified by rheumatic
heart disease [6]. Nevertheless, as anti-apoA-I IgGs have never been shown to be associated with
valvular diseases, these results open a new field of investigations, especially as we could not specify
more in detail with which specific valvular disease these autoantibodies were associated. Furthermore,
as anti-apoA-I IgGs were found to be higher in type 2 diabetic patients and associated with a CVD [17],
the inverse association reported here between the prevalence of diabetes across anti-apoA-I IgG
quartiles was unexpected and thus requires further confirmation. Of note, we did not retrieve any
association between anti-apoA-I IgG and hs-CRP levels, despite previous reports, notably in the general
population, where such association was retrieved [11]. Because anti-apoA-I IgG has been shown to
promote various inflammatory cytokines production [10], including interleukin-6 regulating CRP liver
production, this absence of association was unexpected. The reason for such difference is unknown
and may be explained by differences related to the acute phase the samples of ACS patients were taken
when compared to the stable situation of CoLaus individuals.
On the other hand, the inverse associations retrieved between these antibodies and lymphocyte
and platelet counts are similar to what has been retrieved in HIV patients [36], and the possible causal
nature of such associations is still under investigation. The inverse association between anti-apoA-I
IgGs and eosinophil counts has not been reported. Whether patients with high anti-apoA-I IgG levels
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could be less prone to develop an allergic coronary syndrome (known as the Kounis syndrome) [37]
should be further explored. The weak but significant positive anti-apoA-I IgG correlation with
NT-proBNP, one of the strongest prognostic biomarkers of mitigated prognosis, may be related to the
prognostic value previously ascribed to anti-apoA-I IgGs in different settings [11–17,20–22]. Because
experimental evidence indicates that these autoantibodies could per se promote atherogenesis and
atherothrombosis, as well as mitigate mouse survival by eliciting sterile inflammation through TLR2/4
and CD14 signaling [22–25], the present results reinforce the notion that anti-apoA-I IgGs could
represent a future therapeutic target rather than a mere innocent bystander. Nevertheless, due to the
non-linear relationship between these antibodies and MACE, knowing whether and how assessing
anti-apoA-I IgG levels could affect current medical practice remains to be demonstrated.
The major limitation of this study relies on the fact that we did not assess other auto-antibodies of
potential CV relevance, which is outside of the scope of the present work. The strength of the study
relies on the fact that so far, it represents the largest and best characterized ACS cohort studying the
prognostic value of anti-apoA-I IgGs in ACS.
5. Conclusions
In conclusion, anti-apoA-I IgGs are associated with incident MACE in ACS, independently of the
GRACE 2.0 score, and with a nonlinear relationship to the hazards. Whether anti-apoA-I IgGs could
provide incremental information over the existing risk stratification tool still needs to be determined.
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